ClinicalTrials.gg
RecruitingNCT05142423Updated Mar 12, 2025

A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of AK109+AK104 in Advanced Solid Tumor, sponsored by Akeso. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by Akeso · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
198
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a multi-center, open label, phase Ib/II clinical study of AK109 and AK104 to evaluate the safety, tolerability, effectiveness, pharmacokinetic characteristics in advanced solid tumors .

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written and signed .
  2. Age ≥ 18 years and ≤ 75 years.
  3. Performance Status of 0 or 1.
  4. Estimated of ≥3 months.
  5. or cytologically documented, locally advanced or solid tumours (NSCLC, mCRC, HCC, GEJ, etc. ), for which standard therapy does not exist or has proven ineffective or intolerable.
  6. At least one radiographically per 1.1.
  7. Tumor (during advanced stage) available.
  8. Adequate organ function.
  9. Female participants of and male partners with female partners of childbearing potential must agree to use effective barrier methods of during the study and for 120 days after last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Other documented active other than for this trial within 3 years.
  2. Participation in other clincial trials simultaneously.
  3. Use of systemic anti-tumor treatments with 4 weeks, non-specific immunomodulating agents within 2 weeks.
  4. Prior exposure to other T cell coregulatory proteins except for /PD-L1 inhibitors (apart from cohort B, i.e. treatment naive HCC patients).
  5. Current use / agents, permanently discontinuation of study drug, or having any unresolved irAEs (≥grade 2) from prior PD-1/PD-L1 inhibitors treatment.
  6. Central nervous system (CNS) , meningeal metastasis, spinal cord compression, or .
  7. Uncontrolled pleural/pericardial or peritoneal effusion.
  8. History of hemorrhagic event need blood transfusion, invasive approaches to intervene, or hospitalization within 3 months, or having high risks of bleeding.
  9. Any thromboembolic event, non-gastrointestinal fistula or female genital tract fistula within 6 months.
  10. Uncontrolled gastrointestinal diseases.
  11. Use of NSAIDs and anticoagulant agents within 7 days.
  12. Major surgical procedure, open , or significant traumatic injury within 4 weeks.
  13. Severe or uncontrolled hypertension and cardiovascular/cerebrovascular diseases.
  14. Uncontrolled comorbidities need corticosteroids using.
  15. Active or prior disease or history of immunodeficiency.
  16. History of interstitial lung disease.
  17. Known history of active tuberculosis (TB).
  18. Evidence of active infections including and C.
  19. Use of anti-infectious agents within 2 weeks.
  20. History of (HIV) infections.
  21. Active syphilis infections.
  22. Any unresolved toxicities (≥grade 2) from previous anti-cancer therapies.
  23. Mental illness, drug abuse, or alcohol dependence that may affect compliance with the test requirements.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
198 participants (estimated)

Study arms

  • Experimental
    AK109+AK104

    AK104: 10mg/kg (d1, q3w); AK109: 10mg/kg or 15mg/kg(d1, q3w)

    Drug: AK109+AK104

Interventions

  • DrugAK109+AK104

    Drug pages: Pulocimab · Cadonilimab

    It includes dose escalation and dose expansion stage. 6-12 patients will be enrolled in dose escalation stage for safety and efficacy. Then select specific dose of AK104 and AK109. Expand for the further safety and efficacy study.

06

What researchers measure

Primary outcomes

  1. Number of subjects experiencing dose-limiting toxicities(DLTs)

    DLTs will be assessed during the first 21 days of treatment and are defined as toxicities that meet pre-defined severity criteria, and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications.

    Time frame: Up to 21 days

  2. Incidences and severity of AE

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: Up to 2 years

  3. Objective response rate (ORR)

    The ORR is defined as the proportion of subjects with CR or PR, based on RECIST Version 1.1.

    Time frame: Up to 2 years

Secondary outcomes

  1. Progression-free survival (PFS)

    PFS is defined as the time from the date of first dosing till the first documentation of disease progression (per RECIST v1.1) or death from any cause (whichever occurs first)

    Time frame: Up to 2 years

  2. Disease control rate (DCR)

    DCR is defined as the proportion of subjects with CR, PR, or SD, based on RECIST v1.1

    Time frame: Up to 2 years

  3. Duration of response (DoR)

    Duration of response is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.

    Time frame: Up to 2 years

  4. Time to response (TTR)

    Time to response (TTR) is defined as the time from the start of the treatment to the first objective tumor response observed for patients who achieved CR or PR, as determined by the investigator according to RECIST v1.1.

    Time frame: Up to 2 years

  5. Overall survival (OS)

    OS defined as the time from the first dose to death from any cause. Subjects who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.

    Time frame: Up to 2 years

  6. Correlation analysis of PD-L1 expression with efficacy

    Characteristics of tumor tissue PD-L1 expression and exploratory analysis of correlation between PD-L1 expression status and efficacy.

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
  • First affliated hospital of Zhejiang University
    Hangzhou, Zhejiang, China
    Recruiting
    • Nong Xu, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2021 (actual). Primary completion is estimated for Apr 2027, 65 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2021
First posted
Dec 2, 2021
StartActual
Nov 3, 2021
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05142423
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Dec 2, 2021
Start date
Nov 3, 2021
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Mar 12, 2025

Study contacts

Ting Liu, MD
Contact
clinicaltrials@akesobio.com
+86 (0760) 8987 3999
Nong Xu, MD
principal investigator · The First Affiliated Hospital of Medicine College, Zhejiang University
Jianming Xu, MD
principal investigator · The Chinese PLA General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pulocimab · Cadonilimab

Start the discussion